Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study

BACKGROUND: The United States Preventive Services Task Force supports individualised decision-making for prostate-specific antigen (PSA)-based screening in men aged 55–69. Knowing how the potential benefits and harms of screening vary by an individual’s risk of developing prostate cancer could infor...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PLoS Med
Hlavní autoři: Callender, Tom, Emberton, Mark, Morris, Steve, Eeles, Ros, Kote-Jarai, Zsofia, Pharoah, Paul D. P., Pashayan, Nora
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2019
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6924639/
https://ncbi.nlm.nih.gov/pubmed/31860675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.1002998
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky